Attached files
| file | filename |
|---|---|
| 8-K - 8-K - Vyant Bio, Inc. | pressrelease2015.htm |
| EX-99.2 - EXHIBIT 99.2 - Vyant Bio, Inc. | q42015slides.htm |
Cancer Genetics, Inc. Announces Strong Fourth Quarter and Full-Year 2015 Results and Provides 2016 Business Update
• | Full-Year 2015 revenues up 77% year-over-year to $18 Million |
• | Fourth Quarter revenues up 36% year-over-year to $5.5 Million |
• | Closed 2015 with strong cash balance of $19.5 Million |
• | Conference call begins at 5:00 p.m. Eastern time today |
RUTHERFORD, N.J., March 10, 2016 -- Cancer Genetics, Inc. (Nasdaq:CGIX), an emerging leader in enabling precision medicine for oncology diagnostics, announced financial and operating results for the fourth quarter and full-year-ended December 31, 2015 and provided an update on the business progress for 2016.
“Our business continues to scale as we integrate the acquisition of Response Genetics, focus on expanding our biopharma partnerships, and enhance our capabilities to provide both comprehensive immuno-oncology and genomic testing for oncology,” said Panna Sharma, CEO & President of Cancer Genetics, Inc. “In addition, CGI’s presence is growing both clinically and among biopharma companies - our teams are currently working with 8 of the top 10 pharma companies, and we have agreements with 24 payers, managed care providers, and insurance companies that cover nearly 180 million lives.”
Highlights for the quarter and year included:
▪ | Fourth quarter revenues were $5.5 million, up 36% from $4.0 million in the fourth quarter of 2014 with $3.0 million from BioPharma Services, $2.4 million from Clinical Services, and $0.2 million from Discovery Services |
▪ | Full-Year revenue for 2015 was $18.0 million, up 77% from $10.2 million for the 12-months ended December 31, 2014 |
◦ | BioPharma Services revenue, was $11.6 million, an increase of 106% from $5.6 million over 2014 |
◦ | Clinical Services revenue was $5.7 million compared to $4.4 million during 2014 |
◦ | Discovery Services generated $0.8 million in revenue |
◦ | Gross profit margins improved to 22%, or $3.9 million, as compared to 17%, or $1.7 million, in the 12-months ended December 31, 2014 |
◦ | Cash & cash equivalents at December 31, 2015, were $19.5 million, as compared to $25.6 million at December 31, 2014 |
“As we look ahead in 2016, we see multiple growth drivers impacting our business. The increasing number of oncology clinical trials utilizing both genomic and immune-based markers is expected to continue to drive strong demand for our products and services. In addition, our ability to offer a comprehensive oncology-focused menu of tests, positions us as an ideal partner for healthcare systems,” continued Mr. Sharma. “We will also be launching a number of innovative tests in 2016, including a multiple myeloma panel with the Mayo Clinic, a NGS-based lung cancer panel and a NGS-based panel for hereditary cancers. We have established a global infrastructure, collaborative relationships with academic and research centers, and a strong portfolio of proprietary genomic tests and capabilities.”
KEY 2015 ACHIEVEMENTS & RECENT CORPORATE HIGHLIGHTS
▪ | Awarded largest clinical trial in company history to provide comprehensive testing for global, multi-year Chronic Lymphocytic Leukemia trial |
▪ | Closed $12 million public offering to strengthen balance sheet |
▪ | Acquisition of the operations & assets of Response Genetics, Inc. (RGI) included the FDA-cleared Tissue-Of-Origin test. The RGI acquisition is expected to add $10 million in annual revenue during 2016 |
▪ | Launched a Next-Generation Sequencing (NGS)-based panel targeting the five most common solid tumors for the East Indian and Asian markets |
▪ | Launched Focus::Myeloid™, a comprehensive NGS-based genomic panel for the improved diagnosis, prognosis, and clinical management of myeloid cancer patients |
▪ | Entered into a strategic alliance with the Laboratory Services group of ICON plc, the global CRO (Nasdaq:ICLR), further expanding CGI’s global reach |
▪ | Launched comprehensive immuno-oncology testing portfolio for both solid tumors and blood based cancers |
▪ | Received $1.2 million in non-dilutive funding through the New Jersey Technology Business Tax Certificate Transfer (NOL) Program |
▪ | Presented results from collaborative studies with partners including CGI’s joint venture with Mayo Clinic, Oncospire Genomics, in addition to Memorial Sloane Kettering, Beth Israel Deaconess, Keck School of Medicine at USC, and Weill Cornell Medical College |
Conference Call & Webcast
Thursday, March 10th @ 5:00pm Eastern Time
Domestic: 888-438-5525
International: 888-438-5525
Conference ID: 9859224
Webcast: http://public.viavid.com/index.php?id=118421
Replays - Available through March 24, 2016
Domestic: 877-870-5176
International: 858-384-5517
Conference ID: 9859224
About Cancer Genetics
Cancer Genetics Inc. is a leader in enabling precision medicine in oncology from bench to bedside through the use of oncology biomarkers and molecular testing. CGI is developing a global footprint with locations in the US, India and China. We have established strong clinical research collaborations with major cancer centers such as Memorial Sloan Kettering, The Cleveland Clinic, Mayo Clinic, Keck School of Medicine at USC and the National Cancer Institute.
The Company offers a comprehensive range of laboratory services that provide critical genomic and biomarker information. Its state-of-the-art reference labs are CLIA-certified and CAP-accredited in the US and have licensure from several states including New York State.
For more information, please visit or follow CGI at:
Internet: http://www.cancergenetics.com
Twitter: @Cancer_Genetics
Facebook: www.facebook.com/CancerGenetics
Forward Looking Statements
This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development and potential opportunities for Cancer Genetics, Inc. products and services, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements.
Any statements that are not historical fact (including, but not limited to, statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, risks of cancellation of customer contracts or discontinuance of trials, risks that anticipated benefits from acquisitions will not be realized, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, maintenance of intellectual property rights and other risks discussed in the Cancer Genetics, Inc. Forms 10-K for the year ended December 31, 2014 and 10-Q for the quarter ended September 30, 2015 along with other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Cancer Genetics, Inc. disclaims any obligation to update these forward-looking statements.
Contact:
Media Contact: Investor Contact:
Cancer Genetics, Inc. LifeSci Advisors, LLC
Marie-Agnes Patrone-Michellod, PhD. Hans Vitzthum
Tel: 201.528.9200 212-915-2568
Email: marie.michellod@cgix.com hans@lifesciadvisors.com
CANCER GENETICS, INC. AND SUBSIDIARIES
Consolidated Balance Sheets
(in thousands, except par value)
December 31, | ||||||||
2015 | 2014 | |||||||
ASSETS | ||||||||
CURRENT ASSETS | ||||||||
Cash and cash equivalents | $ | 19,459 | $ | 25,554 | ||||
Accounts receivable, net of allowance for doubtful accounts of 2015 $664; 2014 $251 | 6,621 | 5,028 | ||||||
Other current assets | 2,118 | 1,173 | ||||||
Total current assets | 28,198 | 31,755 | ||||||
FIXED ASSETS, net of accumulated depreciation | 6,069 | 4,310 | ||||||
OTHER ASSETS | ||||||||
Restricted cash | 300 | 6,300 | ||||||
Patents and other intangible assets, net of accumulated amortization | 1,727 | 503 | ||||||
Investment in joint venture | 341 | 1,048 | ||||||
Goodwill | 12,029 | 3,187 | ||||||
Other | 220 | 2 | ||||||
Total other assets | 14,617 | 11,040 | ||||||
Total Assets | $ | 48,884 | $ | 47,105 | ||||
LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) | ||||||||
CURRENT LIABILITIES | ||||||||
Accounts payable and accrued expenses | $ | 7,579 | $ | 3,763 | ||||
Obligations under capital leases, current portion | 122 | 59 | ||||||
Deferred revenue | 831 | 544 | ||||||
Bank term note, current portion | 1,333 | — | ||||||
Total current liabilities | 9,865 | 4,366 | ||||||
Obligations under capital leases | 276 | 300 | ||||||
Deferred rent payable and other | 315 | 348 | ||||||
Line of credit | — | 6,000 | ||||||
Warrant liability | 17 | 52 | ||||||
Acquisition note payable | — | 560 | ||||||
Deferred revenue, long-term | 752 | 925 | ||||||
Bank term note | 4,642 | — | ||||||
Total Liabilities | 15,867 | 12,551 | ||||||
STOCKHOLDERS’ EQUITY | ||||||||
Preferred stock, authorized 9,764 shares $0.0001 par value, none issued | — | — | ||||||
Common stock, authorized 100,000 shares, $0.0001 par value, 13,652 and 9,821 shares issued and outstanding as of December 31, 2015 and 2014, respectively | 1 | 1 | ||||||
Additional paid-in capital | 131,167 | 112,520 | ||||||
Accumulated deficit | (98,151 | ) | (77,967 | ) | ||||
Total Stockholders’ Equity | 33,017 | 34,554 | ||||||
Total Liabilities and Stockholders’ Equity | $ | 48,884 | $ | 47,105 | ||||
CANCER GENETICS, INC. AND SUBSIDIARIES
Consolidated Statements of Operations
(in thousands, except per share amounts)
Three Months Ended December 31 | Twelve Months Ended December 31 | ||||||||||||||
2015 | 2014 | 2015 | 2014 | ||||||||||||
Revenue | $ | 5,484 | $ | 4,035 | $ | 18,040 | $ | 10,199 | |||||||
Cost of revenues | 4,756 | 3,094 | 14,098 | 8,453 | |||||||||||
Gross profit | 728 | 941 | 3,942 | 1,746 | |||||||||||
Operating expenses: | |||||||||||||||
Research and development | 1,148 | 1,529 | 5,483 | 4,622 | |||||||||||
General and administrative | 5,031 | 4,138 | 14,567 | 12,369 | |||||||||||
Sales and marketing | 1,726 | 1,226 | 5,269 | 3,964 | |||||||||||
Total operating expenses | 7,905 | 6,893 | 25,319 | 20,955 | |||||||||||
Loss from operations | (7,177 | ) | (5,952 | ) | (21,377 | ) | (19,209 | ) | |||||||
Other income (expense): | |||||||||||||||
Interest expense | (117 | ) | (65 | ) | (344 | ) | (473 | ) | |||||||
Interest income | 19 | 17 | 49 | 74 | |||||||||||
Change in fair value of warrant liability | 17 | 93 | 35 | 417 | |||||||||||
Change in fair value of acquisition note payable | 360 | 198 | 269 | 198 | |||||||||||
Total other income (expense) | 279 | 243 | 9 | 216 | |||||||||||
Loss before income taxes | (6,898 | ) | (5,709 | ) | (21,368 | ) | (18,993 | ) | |||||||
Income tax (benefit) | (1,184 | ) | (536 | ) | (1,184 | ) | (2,350 | ) | |||||||
Net (loss) | $ | (5,714 | ) | $ | (5,173 | ) | $ | (20,184 | ) | $ | (16,643 | ) | |||
Basic net (loss) per share | $ | (0.47 | ) | $ | (0.54 | ) | $ | (1.96 | ) | $ | (1.76 | ) | |||
Diluted net (loss) per share | $ | (0.48 | ) | $ | (0.55 | ) | $ | (1.96 | ) | $ | (1.80 | ) | |||
Basic weighted average shares outstanding | 12,048 | 9,642 | 10,298 | 9,449 | |||||||||||
Diluted weighted average shares outstanding | 12,048 | 9,642 | 10,299 | 9,462 | |||||||||||
CANCER GENETICS, INC. AND SUBSIDIARIES
Consolidated Statements of Cash Flows
(in thousands)
Years Ended December 31, | ||||||||
2015 | 2014 | |||||||
CASH FLOWS FROM OPERATING ACTIVITIES | ||||||||
Net loss | $ | (20,184 | ) | $ | (16,643 | ) | ||
Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
Depreciation | 1,503 | 810 | ||||||
Amortization | 159 | 28 | ||||||
Provision for bad debts | 413 | 215 | ||||||
Stock-based compensation | 2,834 | 3,835 | ||||||
Change in fair value of acquisition note payable | 269 | (198 | ) | |||||
Change in fair value of Gentris contingent consideration | (207 | ) | — | |||||
Change in fair value of warrant liability | (35 | ) | (417 | ) | ||||
Amortization of loan guarantee, financing fees and debt issuance costs | 8 | 311 | ||||||
Loss in equity-method investment | 707 | 940 | ||||||
Change in working capital components: | ||||||||
Accounts receivable | (1,662 | ) | (1,657 | ) | ||||
Other current assets | (384 | ) | (199 | ) | ||||
Other non-current assets | (101 | ) | — | |||||
Accounts payable, accrued expenses and deferred revenue | 3,114 | 675 | ||||||
Deferred rent and other | (33 | ) | (38 | ) | ||||
Net cash (used in) operating activities | (13,599 | ) | (12,338 | ) | ||||
CASH FLOWS FROM INVESTING ACTIVITIES | ||||||||
Purchase of fixed assets | (1,008 | ) | (1,374 | ) | ||||
(Increase) decrease in restricted cash | 6,000 | (6,000 | ) | |||||
Patent costs | (137 | ) | (130 | ) | ||||
Investment in joint venture | — | (1,000 | ) | |||||
Cash used in acquisition of Gentris, net of cash received | — | (3,181 | ) | |||||
Cash from acquisition of BioServe | — | 312 | ||||||
Cash used in acquisition of Response Genetics | (7,495 | ) | — | |||||
Net cash (used in) investing activities | (2,640 | ) | (11,373 | ) | ||||
CASH FLOWS FROM FINANCING ACTIVITIES | ||||||||
Principal payments on capital lease obligations | (83 | ) | (44 | ) | ||||
Payment of equity issuance costs | (117 | ) | — | |||||
Proceeds from public offerings of common stock, net of offering costs | 10,353 | — | ||||||
Proceeds from warrant exercises | 1 | 178 | ||||||
Proceeds from option exercises | 23 | 79 | ||||||
Payment of debt issuance costs | (33 | ) | — | |||||
Principal payments on notes payable | — | (408 | ) | |||||
Net cash provided by (used in) financing activities | 10,144 | (195 | ) | |||||
Net increase (decrease) in cash and cash equivalents | (6,095 | ) | (23,906 | ) | ||||
CASH AND CASH EQUIVALENTS | ||||||||
Beginning | 25,554 | 49,460 | ||||||
Ending | $ | 19,459 | $ | 25,554 | ||||
SUPPLEMENTAL CASH FLOW DISCLOSURE | ||||||||
Cash paid for interest | $ | 240 | $ | 128 | ||||
SUPPLEMENTAL DISCLOSURE OF NONCASH | ||||||||
INVESTING AND FINANCING ACTIVITIES | ||||||||
Fixed assets acquired through capital lease arrangements | $ | — | $ | 42 | ||||
Value of shares issued as partial consideration to purchase Gentris and BioServe | — | 1,516 | ||||||
Value of shares issued as partial consideration to purchase Response Genetics | 5,436 | — | ||||||
Cashless exercise of derivative warrants | — | 125 | ||||||
Net tangible assets acquired via acquisition | 2,843 | 1,255 | ||||||